By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
Keep in mind that the secondary endpoint of ACR 50 response was also reached in the TCZ + MTX and TCZ monotherapy groups. The average MTX dose was around 11mg q week in both TCZ+MTX and MTX + Placebo groups. That may sound low compared to MTX doses used in the USA, but reducing the MTX when used in combination with TCZ may help reduce AE such as Leukopenia and LFT elevations. Overall a nice study.